Methodological issues in pharmacokinetic-pharmacodynamic modelling

被引:41
|
作者
Bellissant, E
Sébille, V
Paintaud, G
机构
[1] Fac Med, Lab Pharmacol Expt & Clin, F-35043 Rennes, France
[2] Hop Brettoneau, Lab Pharmacol & Toxicol, Tours, France
关键词
D O I
10.2165/00003088-199835020-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This article presents the theoretical and practical aspects involved in the design and analysis of pharmacokinetic-pharmacodynamic modelling studies. The main features of the protocol of pharmacokinetic-pharmacodynamic studies are discussed with special focus on experimental designs in relation to individual and population approaches. Some basic pharmacodynamic models (such as linear, log-linear, hyperbolic and sigmoid models) are presented as well as more complex time-dependent models (effect compartment and physiological indirect response, tolerance models) which are required when the concentration-effect relationship shows a hysteresis loop. The methods of estimation, with special focus on the individual and populations approaches, are covered, along with the way pharmacodynamic models and methods of estimation can be applied to real data and the information required to criticise the results of modelling. We also present some real problems frequently encountered when performing pharmacokinetic-pharmacodynamic modelling and give some potential solutions (problems with hysteresis loops, lack of convergence, problems with residuals). The last section discusses the significance of pharmacodynamic parameters.
引用
收藏
页码:151 / 166
页数:16
相关论文
共 50 条
  • [31] PHARMACOKINETIC-PHARMACODYNAMIC MODELING IN PAIN
    Loetsch, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 14 - 14
  • [32] Pharmacokinetic-Pharmacodynamic Modelling of Ketamine in Six Neurotraumatised Intensive Care Patients
    Youssef Hijazi
    Carole Bodonian
    François Salord
    Françoise Bressolle
    Roselyne Boulieu
    Clinical Drug Investigation, 2003, 23 : 605 - 609
  • [33] A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine
    Urien, S
    Tillement, JP
    Ganem, B
    Kuch, MD
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1999, 37 (10) : 499 - 502
  • [34] Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses
    Friberg, LE
    Isbister, GK
    Duffull, SB
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (02) : 177 - 190
  • [35] Pharmacokinetic-Pharmacodynamic Modelling of the Antipyretic Effect of Two Oral Formulations of Ibuprofen
    Iñaki F. Trocóniz
    Santos Armenteros
    María V. Planelles
    Julio Benítez
    Rosario Calvo
    Rosa Domínguez
    Clinical Pharmacokinetics, 2000, 38 : 505 - 518
  • [36] Pharmacokinetic-pharmacodynamic modelling of the antinociceptive effect of a romifidine infusion in standing horses
    Bernal, Sabina Diez
    Studer, Nicole
    Thormann, Wolfgang
    Spadavecchia, Claudia
    Levionnois, Olivier
    VETERINARY ANAESTHESIA AND ANALGESIA, 2020, 47 (01) : 129 - 136
  • [37] Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations
    Brill, M. J. E.
    Kristoffersson, A. N.
    Zhao, C.
    Nielsen, E. I.
    Friberg, L. E.
    CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (07) : 697 - 706
  • [38] Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis
    Tan, Jiun Ming
    Upton, Richard N.
    Foster, David J. R.
    Proudman, Susanna M.
    Dhir, Varun
    Wiese, Michael D.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [39] Pharmacokinetic-Pharmacodynamic Modelling of Recombinant Human Erythropoietin in AthletesA Population Approach
    A. Gaudard
    E. Varlet-Marie
    M. Audran
    R. Gomeni
    F. Bressolle
    Clinical Drug Investigation, 2003, 23 : 167 - 179
  • [40] Pharmacokinetic-pharmacodynamic modelling to investigate herb-drug interactions with warfarin
    Jiang, X
    Williams, KM
    Liauw, W
    Ammit, AJ
    Roufogalis, BD
    Duke, CC
    Day, RO
    McLachlan, AJ
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (11) : A227 - A227